Cyclophosphamide
Aplastic Anemia
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Aplastic Anemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evomela Masonic Cancer Center, University of Minnesota | Phase 2 | BB |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2 | BB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Basiliximab Indiana University | Phase 2 | B |
Campath University of Chicago | Phase 2 | B |
View all 23 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →